USANA Health Sciences Files 8-K on Financials

Ticker: USNA · Form: 8-K · Filed: 2025-02-25T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

USANA Health Sciences dropped an 8-K on Feb 25, 2025, detailing financial results and operations.

AI Summary

USANA Health Sciences, Inc. filed an 8-K on February 25, 2025, to report on its results of operations and financial condition. The filing also includes information related to Regulation FD and financial statements and exhibits. The company is incorporated in Utah and its principal executive offices are located in Salt Lake City.

Why It Matters

This 8-K filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational results, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any unusual or significant risks.

Key Players & Entities

USANA HEALTH SCIENCES INC (company) — Registrant
February 25, 2025 (date) — Date of Report
Utah (location) — State of Incorporation
Salt Lake City (location) — Principal Executive Offices City
3838 West Parkway Boulevard (address) — Principal Executive Offices Street

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the results of operations and financial condition of USANA Health Sciences, Inc.

When was this 8-K report filed?

This 8-K report was filed on February 25, 2025.

In which state is USANA Health Sciences, Inc. incorporated?

USANA Health Sciences, Inc. is incorporated in Utah.

What is the address of USANA Health Sciences, Inc.'s principal executive offices?

The principal executive offices of USANA Health Sciences, Inc. are located at 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.

What other information is included in this 8-K filing besides financial results?

This 8-K filing also includes information related to Regulation FD Disclosure and Financial Statements and Exhibits.

From the Filing

0000896264-25-000054.txt : 20250225 0000896264-25-000054.hdr.sgml : 20250225 20250225161123 ACCESSION NUMBER: 0000896264-25-000054 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250225 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 25663223 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20250225.htm 8-K usna-20250225 FALSE 0000896264 0000896264 2025-02-25 2025-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 25, 2025 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission File No.) (IRS Employer Identification No.) 3838 West Parkway Boulevard Salt Lake City , Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: ( 801 ) 954-7100 Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share USNA New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition. On February 25, 2025, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 28, 2024. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving direct